Major Ingredients

Each vial contains Cisplatin BP 50 mg (1 mg/ml)

Major Functionality

Neoplat injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors - In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radio therapeutic procedures. Metastatic Ovarian Tumors- In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radio therapeutic procedures. An established combination consists of Neoplat (Cisplatin) and cyclophosphamide. Neoplat, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin Injection therapy. Advanced Bladder Cancer - Neoplat (Cisplatin) is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments such as surgery and/or radiotherapy. Non Small Cell Lung Carcinoma- Neoplat (Cisplatin) in combination with other chemotherapeutic agent is indicated for the treatment of non small cell lung cancer in patients who are not candidates for potential curative surgery and/ or radiation therapy. Dosage and Administration: Cisplatin injection is administered by slow intravenous infusion. It should not be given by rapid intravenous injection. Note: Needles or intravenous sets containing aluminum parts that may come in contact with Cisplatin Injection should not be used for preparation or administration. Aluminum reacts with Cisplatin Injection, causing precipitate formation and a loss of potency. Metastatic Testicular Tumors- The usual Cisplatin Injection dose for the treatment of testicular cancer in combination with other approved chemotherapeutic agents is 20 mg/m2 IV daily for 5 days per cycle. Metastatic Ovarian Tumors- The usual Cisplatin Injection dose for the treatment of met

Manufacture Information

Drug International Limited was incorporated under the Registrar of Joint Stock Companies in 1974 as a Private Limited Company. The company commenced formulation and production in 1983 and emerged as a pioneer in Bangladesh for adding a state of the art oral solid dosage plant. Since inception, Drug International Limited's primary objective has been to meet guidelines provided by major global regulatory bodies such as the World Health Organization Good Manufacturing Practices (WHO cGMP) guidelines.